Ionis Pharmaceuticals Inc (NAS:IONS)
$ 38.3 -0.5 (-1.29%) Market Cap: 5.59 Bil Enterprise Value: 4.90 Bil PE Ratio: 0 PB Ratio: 18.87 GF Score: 70/100

Ionis Pharmaceuticals Inc at Stifel CNS Days (Virtual) Transcript

Mar 28, 2022 / 03:00PM GMT
Release Date Price: $35.88 (-2.15%)
Paul Andrew Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst

Great. Thanks very much, everybody, for continuing on. It's my pleasure to be hosting Eric Swayze, Executive Vice President of Research at Ionis; and Holly Kordasiewicz, who runs their neurology research group. We have a lot of stuff to get into, a lot of programs. We can talk maybe a little bit about today's data release as well and any implications.

Questions & Answers

Paul Andrew Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst

But do you want to maybe just kick it off, either Eric or Holly, and just talk a bit about your neuro pipeline right now and where the different programs stand?

Eric E. Swayze
Ionis Pharmaceuticals, Inc. - EVP of Research

Yes. I'd love to do that, and thanks for having us on, Paul. I think that a little overview of our neuro portfolio strategy and depth is

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot